About Us
A First-in-Class Therapy, Now in Clinical Trials
PHASE I CLINICAL TRIAL UNDERWAY
Our Phase I trial, PHAROS, has begun dosing patients with prostate cancer — marking the first-ever clinical test of an ACK1 inhibitor. This milestone moves (R)-9b from a promising preclinical candidate into real-world validation, with initial proof-of-concept data expected in Q1 2026 and full trial completion expected Q1 2027.
NOW RECRUITING PATIENTS
The PHAROS trial is actively enrolling patients with prostate cancer to evaluate the safety and tolerability of (R)-9b. Eligible patients and referring physicians can find enrollment details, eligibility criteria, and trial site information through the official clinical trial listing.
View Trial & Enrollment Details ↗TechnoGenesys, Inc. is focused on commercialization of a novel anti-cancer inhibitor (R)-9b, which has dual properties: an Androgen Receptor (AR) antagonist with immune-regulatory activity. TechnoGenesys is also committed to providing novel companion diagnostics (CDx) that accurately predict response to treatment with (R)-9b, in a personalized medicine approach.
Key reasons to invest in TechnoGenesys
First in a new therapeutic class
We are the first developer of a 'dual' prostate cancer drug — a rapidly developing therapeutic area with a huge market.
High unmet medical need
1.4 million new cases of prostate cancer and over 375,000 related deaths were reported in 2020 globally. The large majority of cancer-related deaths are due to drug resistance.
First-in-class mechanism
There are currently no ACK1 inhibitors on the market, and our compound (R)-9b is the first in this class.
De-risked clinical asset
Multiple upcoming value inflection points: initial clinical proof-of-concept expected Q1 2026 (First-in-human, Phase I), with trial completion expected Q1 2027.
Highly focused clinical development
A focused early-stage dataset for value creation, with opportunities to broaden into 3 other cancer indications (breast and lung cancer).
Experienced leadership
A leadership team with a clear track record from biotech and pharma, backed by a prominent clinical advisory board.
Comprehensive patent protection
We have secured long patent protection of our lead asset, and are diligently expanding and strengthening our IP portfolio.